| Phase 11 trial |
|
Phase 1
|
NCT02527746 |
Dec 2012 → Dec 2013 |
breast cancer, neutropenia |
EVIVE Biotechnology |
Completed
|
No outcome recorded
|
| Phase 1/21 trial |
|
Phase 1/2
|
NCT02522234 |
Feb 2014 → Aug 2015 |
neutropenia |
EVIVE Biotechnology |
Completed
|
No outcome recorded
|
| Phase 25 trials |
|
Phase 2
|
NCT07187908 |
Jan 2025 → Oct 2026 expected |
chemotherapy-induced toxicity |
Henan Cancer Hospital |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06251947 |
Apr 2024 → Jun 2026 overdue |
cervical cancer, ovarian cancer |
Shandong University |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06134765 |
Nov 2023 → Oct 2024 |
colorectal cancer, malignant pancreatic neoplasm |
Second Affiliated Hospital, School of Medicine, Zhejiang University |
Unknown
|
No outcome recorded
|
|
Phase 2
|
NCT02521441 |
Jul 2014 → Sep 2015 |
neutropenia |
EVIVE Biotechnology |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT01648322 |
Jun 2012 → Dec 2014 |
breast cancer, neutropenia |
EVIVE Biotechnology |
Completed
|
No outcome recorded
|
| Phase 33 trials |
|
Phase 3
|
NCT03252431 |
Apr 2018 → Sep 2019 |
female breast carcinoma, neutropenia |
EVIVE Biotechnology |
Completed
|
No outcome recorded
|
|
Phase 3
|
NCT04174599 |
Apr 2018 → Jan 2019 |
breast cancer, neutropenia |
EVIVE Biotechnology |
Completed
|
No outcome recorded
|
|
Phase 3
|
NCT02872103 |
Aug 2016 → Dec 2017 |
breast cancer, neutropenia |
EVIVE Biotechnology |
Completed
|
No outcome recorded
|
| Phase not applicable1 trial |
| — |
NCT06649448 |
Oct 2024 → Dec 2025 overdue |
neutropenia |
Shandong Cancer Hospital and Institute |
Not yet recruiting
|
No outcome recorded
|